Angiotensin receptor blocker use and gastro‐oesophageal cancer survival: a population‐based cohort study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Background: Angiotensin receptor blockers (ARB s; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy. There is considerable pre‐clinical evidence that ARB s can reduce cancer progression, particularly for gastric cancer. Despite this, epidemiological studies have yet to assess the impact of ARB use on gastro‐oesophageal cancer survival. Aim: To investigate the association between post‐diagnosis ARB use and gastro‐oesophageal cancer survival. Methods: We selected a cohort of patients with newly‐diagnosed gastro‐oesophageal cancer between 1998 and 2012 from English cancer registries. We linked to prescription and clinical records from the Clinical Practice Research Datalink, and to death records from the Office for National Statistics. We used time‐dependant Cox‐regression models to calculate hazard ratios (HR s) comparing gastro‐oesophageal cancer‐specific mortality between post‐diagnosis ARB users and non‐users, after adjusting for demographics, comorbidities and post‐diagnosis aspirin or statin use. Results: Our cohort included 5124 gastro‐oesophageal cancer patients, of which 360 used ARB s, and 3345 died due to their gastro‐oesophageal cancer during follow‐up. After adjustment, ARB users had moderately lower risk of gastro‐oesophageal cancer mortality than the non‐users (HR = 0.83, 95% CI 0.71‐0.98). There was evidence of a dose–response relationship with the lowest HR s observed among patients receiving at least 2 years of prescriptions (HR = 0.42, 95% CI 0.25‐0.72). Conclusions: In this large population‐based gastro‐oesophageal cancer cohort, we found moderately reduced cancer‐specific mortality among ARB users. However, confirmation in further independent epidemiological studies with sufficient staging information is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 2×
“Previous research has found prescription and clinical information to be of high quality.(29) Office for National Statistics death-registration data provide details on the date and cause(s) of death.”
MethodNegative Controls: A Tool for Detecting Confounding and Bias in Observational Studies
Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181d61eeb · Cited by 1,583
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739 · cited 1×
“Third, we compared patients who received ARBs to those who received a different antihypertensive medication after diagnosis (using a time-varying covariate), as the use of an active comparison can overcome several common pharmacoepidemiological biases.(38) Similarly, we conducted negative control analyses(39) for ACE…”
ResultApplication of lag‐time into exposure definitions to control for protopathic bias
Tamim, H., Monfared, A. A. T., & LeLorier, J. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1360 · Cited by 186
Cited by
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers
Kozlova, N., Grossman, J. E., Iwanicki, M. P., & Muranen, T. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.01.001 · Cited by 73
“Losartan has also been implicated in reduced mortality in certain cancers [109, 111], and is being evaluated in clinical trials in locally advanced PDAC in combination with FOLFIRINOX, nivolumab and radiotherapy (Clinical Trial Number: NCT03563248).”
BackgroundRole of the tumor microenvironment in cancer hallmarks and targeted therapy (Review)
Naser, R., Fakhoury, I., El‑Fouani, A., Abi‑Habib, R., & El‑Sibai, M. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5471 · Cited by 61
Metadata
- Authors
- Busby, J., McMenamin, Ú., Spence, A., Johnston, B. T., Hughes, C., & Cardwell, C. R.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-11-03
- Volume
- 47
- Issue
- 2
- Pages
- 279-288
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2761669428
- Cited by
- 40
- References
- 6
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiotensin receptor blocker use and gastro‐oesophageal cancer survival: a population‐based cohort study. https://app.cochat.ai/papers/10.1111/apt.14388
- The paper
- Busby, J., McMenamin, Ú., Spence, A., Johnston, B. T., Hughes, C., & Cardwell, C. R. (2018). Angiotensin receptor blocker use and gastro‐oesophageal cancer survival: a population‐based cohort study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14388
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.